Jun 24 |
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
|
Jun 10 |
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
|
May 15 |
Panbela Therapeutics, Inc. (PBLA) Q1 2024 Earnings Call Transcript
|
May 15 |
Panbela Therapeutics GAAP EPS of -$2.28
|
May 15 |
Panbela Provides Business Update and Reports Q1 2024 Financial Results
|
May 6 |
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
|
May 1 |
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
|
Apr 30 |
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
|
Apr 22 |
Panbela Therapeutics announces delay of expected data from pancreatic cancer treatment trial
|
Apr 22 |
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
|